Evaluation of serum Asprosin in patients with Prediabetes and newly diagnosed type 2 Diabetes Mellitus

Abstract

Background Mammal white adipose tissue secretes asprosin, a protein hormone that causes the liver to release glucose. Asprosin, a protein produced by the gene FBN1, is released from the C-terminus of profibrillin via targeted proteolysis. Asprosin stimulates a cyclic adenosine monophosphate (cAMP)-dependent mechanism that results in fast glucose release in the liver. Objective This study's aim was to provide an estimation of serum concentrations of asprosin in prediabetes, newly diagnosed diabetes mellitus type 2 patients, & healthy controls by ELISA technique. Methods Case-control research carried out at the Teaching Hospital of the Medical City of Baghdad and the AL-Imamain AL-Kadhmain Medical City between March 2021 and March 2022. It included 40 diabetics with type 2 recently diagnosed, forty people who have prediabetes and 40 healthy control persons. Patients with diabetes, prediabetes, and healthy controls each had around 5 ml of blood drawn from a vein. After 15 minutes at room temperature, the 5 mL of blood were analyzed. Centrifugation of the sera about 3000 rpm for ten minutes was used to separate the sera after coagulation. Sera were put in -20 C storage until they could be tested with ELISA kits. Results When compared to patients with prediabetes and controls, individuals with newly diagnosed diabetes type 2 had serum asprosin concentrations that were considerably greater. Conclusion When compared to prediabetic patients and the control group, Type 2 diabetic mellitus newly diagnosed patients had serum asprosin levels that were significantly higher, with a high sensitivity and specificity of the cutoff value for the biomarker.